Skip to main content

Table 3 Cholestasis outcomes by drug treatment

From: Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit

  Phenobarbital Ursodiol p-value
Univariate analysis (first course only)
Change in direct Bilirubin    0.03
 mg/dl +  0.76 −1.89
 umol/L + 13.0 −32.3
Direct Bili at end of drug therapy    0.02
 mg/dl 7.84 4.98
 umol/L 134.1 85.2
Adjusted for direct Bilirubin at start of drug therapy
Change in direct Bilirubin    
 First course    0.01
  mg/dl +  0.81 −1.95
  umol/L +  13.85 - 33.35
 All Courses    <0.01
  mg/dl + 0.66 −3.63
  umol/L + 11.29 −62.08
Direct Bili at end of drug therapy (mg/dl)
 First course    0.01
  mg/dl 7.79 5.03
  umol/L 133.24 86.03
 All Courses    <0.01
  mg/dl 8.27 3.98
  umol/L 141.45 68.07
Adjusted for direct Bilirubin at start of drug therapy, IUGR and limited lipids
Change in direct Bilirubin    
 First course    0.03
  mg/dl + 0.27 −2.16
  umol/L + 4.62 −36.94
 All Courses   
< 0.01
  mg/dl + 0.28 −3.96
  umol/L + 4.79 −67.73
Direct Bili at end of drug therapy (mg/dl)
 First Course    0.03
  mg/dl 7.25 4.83
  umol/L 124.0 82.61
 All Coursesa    < 0.01
  mg/dl 7.89 3.65
  umol/L 134.95 62.43
  1. The first course analysis compares 37 phenobarbital to 31 ursodiol courses. The all course analysis compares 46 phenobarbital to 66 ursodiol courses. aThe all course analysis was also adjusted for a binary variable accounting for previous phenobarbital or ursodiol exposure in prior 14 days